Chemotherapy carboplatin

While carboplatin has the same mechanism of action as cisplatin, it has a much less toxic side-effect profile than cisplatin. The pharmacokinetics of carboplatin are best described by a two-compartment model, with an a half-life of 90 minutes and a terminal half-life of 180 minutes. Carboplatin is eliminated almost entirely by the kidney by glomerular filtration and tubular secretion. Many chemotherapy regimens dose carboplatin based on an area under the curve (AUC), which is referred to... 

JP is receiving a highly myelosuppressive chemotherapy regimen for the next 3 days for his lymphoma. The chemotherapy orders specify ifosfamide, carboplatin, and etoposide. The goal of this cycle of chemotherapy is to put the cancer into remission so that his lymphoma can be cured with a bone marrow transplant. 

In patients who experienced a complete response to first-line chemotherapy and have had greater than a 6-month platinum-free interval, retreatment with a platinum-containing regimen is appropriate. Current National Comprehensive Cancer Network (NCCN) guidelines recommend the combination of carboplatin... 

This 67-year-old patient was optimally debulked and completed six cycles of paclitaxel/carboplatin after her surgery. HerCA-125 normalized (12 U/mL, 12 kU/L) on completion of her chemotherapy treatment, and her CT scan was negative. This patient returns to your clinic for her first 3-month follow-up appointment. Her CA-125 is (45 U/mL, 45 kU/L), and she reports some mild bloating. CT scan report states mild fluid accumulation in the pelvic cavity. 

Four to six cycles of doublet chemotherapy with cisplatin or carboplatin plus docetaxel, gemcitabine, paclitaxel, or vinorelbine are recommended as first-line chemotherapy for patients with unresectable stage III or IV NSCLC. No combination was found to be superior tolerance of expected toxicities may contribute to the decision. 

Cisplatin was the first example of a platinum-based chemotherapeutic but it has been followed by others carboplatin, oxoplatin, and cycloplatam. All are variations on the original theme and all find use in the chemotherapy of cancer. 

Parker RJ, Gill I, Tarone R, et al. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy measured by atomic absorption spectrometry. Carcinogenesis 1991 12 1253-1258. 

Lau et al. have reported on their experience of administering radiation with taxol dosed twice a week for locally advanced nonsmall-cell lung cancer (53). Their phase II trial was conducted combining low-dose radiosensitizing chemotherapy with concurrent radiation followed by consolidation chemotherapy (62). The induction chemoradiation consisted of paclitaxel, 30 mg/m2 iv over 1 h, twice weekly for 6 wk carboplatin, AUC of... 

PR) and median survival was 26 mo. The 3-yr survival probability is 0.47 (64). Because dose escalation was limited to 74 Gy without reaching a maximally tolerated dose, a further trial is underway to find the true MTD of dose-escalated thoracic radiation with concurrent carboplatin-paclitaxel-based chemotherapy. 

K. Radiation therapy and concomitantpaclitaxel/carboplatin chemotherapy formuscle invasive transitional cell carcinoma of the bladder a well-tolerated combination. Int J Cancer 2000 90(5) 281-286. 

WagnerH, AntoniaS, Shaw G, et al. Induction Chemotherapy with Carboplatin and Paclitaxel followed by Hyperfractionated Accelerated Radiation for Patients with Unresectable Stage IIA and IIB Non-Small-Cell Lung Cancer. Proc Am Soc Clin Oncol 1998 17 469a (abstr). 

Muderspach et al. (31) reported the results of a pilot study of concurrent carboplatin (30 mg/m2 twice weekly) with radiation in 22 patients with stage IIA (>4 cm) to IIIB disease. The most significant chemotherapy-related side effects were grade 3 neutropenia and anemia. The authors reported 19 complete responders to this regimen, although only 11 patients were alive and disease-free at the time of their report. Because cisplatin... 

A systematic review in the Cochrane database of forty-nine trials of chemotherapy for advanced ovarian cancer involving 8763 women concluded The available evidence, although not conclusive, suggests that platinum-based chemotherapy is better than non-platinum therapy. There is some evidence that combination therapy improves survival compared with platinum alone. No difference in effect has been shown between cisplatin and carboplatin (see Advanced Ovarian Cancer Trialists Group, 1999). 

Metastatic osteosarcoma has a poor prognosis unless the disease is confined to the lungs and is resectable. Palliative chemotherapy can be employed with a number of drugs including doxorubicin, cisplatin, carboplatin, methotrexate, ifosfamide and etoposide. 

---